Younghee Yun, Med Aromat Plants 2017, 6:6 (Suppl)
DOI: 10.4172/2167-0412-C1-014

Efficacy, safety and dose finding trial of topical Jaungo application in atopic dermatitis patients: A randomized, double-blind, placebo-controlled study

Younghee Yun
CY Pharmaceutical Co., Ltd., Republic of Korea

Atopic Dermatitis (AD) is a common pruritic inflammatory skin disease. In its chronic stage, hyperpigmentation, excoriation, lichenification and dryness are the main symptoms. Jaungo comprises two herbs, *Lithospermi Radix* and *Angelica Gigantis Radix* and three carrier oils and is an approved herbal ointment for xerosis in Korea. In past preclinical studies, we demonstrated that Jaungo had anti-inflammatory and anti-allergic activity. We conducted a randomized, double blind, placebo-controlled, single-center trial with three parallel arms. Trial group-1 applies Jaungo twice a day, while trial group-2 applies Jaungo and the placebo once a day, separately, and the placebo group applies the placebo twice a day, for a total of 3 weeks each. Participants evaluated for eczema based on the eczema area and severity score, the scoring of atopic dermatitis score, the dermatology life quality score, trans-epidermal water loss, total IgE level, eosinophil count and IL-17, IL-22 and IFN-γ levels. The outcomes to evaluate the safety included Draize score and blood test. In total, 28 patients (82.4%) completed the study. Significant decline of EASI scores in trial group-2 and placebo group was observed ($p<0.05$). There was significant decline of SCORAD scores in trial group-1 and placebo group ($p<0.05$). However, patients in all groups showed decreased TEWL and DLQI scores with no significant difference. No clinically relevant changes in laboratory values were observed except IL-17. There was significant decline of IL-17 in all groups ($p<0.05$). Inter-group analysis showed no significant difference. No serious adverse event was observed.

Biography

Younghee Yun has completed her PhD from College of Traditional Korean Medicine, Kyung Hee University in Korea. She has published more than 12 papers. Currently she is the CEO of CY Pharmaceutical Co., Ltd. Her main interest is atopic dermatitis, allergic skin disease and pharmacological action of herbal medicine.

younghee.yun@hanmail.net

Notes: